Acrivon Therapeutics (ACRV) Total Liabilities (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Total Liabilities of $12.3 million for Q1 2026, down 22.82% year-over-year from $16.0 million in Q1 2025, and down 28.39% quarter-over-quarter from $17.2 million in Q4 2025.
Acrivon Therapeutics (ACRV) Total Liabilities (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Total Liabilities for 6 consecutive years, with $12.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 22.82% year-over-year to $12.3 million; the TTM figure through Mar 2026 stood at $12.3 million (down 22.82% YoY), while the FY2025 annual figure was $17.2 million, down 13.14% from the prior year.
- Total Liabilities fell to $12.3 million in Q1 2026 per ACRV's latest filing, from $17.2 million in the prior quarter.
- Across five years, Total Liabilities topped out at $19.8 million in Q4 2024 and bottomed at $9.7 million in Q1 2023.
- Historically, Total Liabilities has averaged $14.3 million across 5 years, with a median of $14.5 million in 2024.
- Annual changes were most pronounced in 2023 — Total Liabilities surged 58.78% — and 2026, when it declined 22.82%.
- Acrivon Therapeutics' Total Liabilities stood at $10.8 million in 2022, then soared by 58.78% to $17.1 million in 2023, then advanced by 16.0% to $19.8 million in 2024, then decreased by 13.14% to $17.2 million in 2025, then retreated by 28.39% to $12.3 million in 2026.
- Business Quant data shows ACRV's Total Liabilities at $12.3 million in Q1 2026, $17.2 million in Q4 2025, and $16.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Acrivon Therapeutics | 92.26 Mn | 92.26 Mn | - | 12.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.43 Mn |
| Mar 31, 2026 | 12.32 Mn |
| Dec 31, 2025 | 17.20 Mn |
| Sep 30, 2025 | 16.70 Mn |
| Jun 30, 2025 | 15.55 Mn |
| Mar 31, 2025 | 15.96 Mn |
| Dec 31, 2024 | 19.80 Mn |
| Sep 30, 2024 | 17.79 Mn |
| Jun 30, 2024 | 14.53 Mn |
| Mar 31, 2024 | 12.54 Mn |
| Dec 31, 2023 | 17.07 Mn |
| Sep 30, 2023 | 12.94 Mn |
| Jun 30, 2023 | 10.87 Mn |
| Mar 31, 2023 | 9.73 Mn |
| Dec 31, 2022 | 10.75 Mn |
| Sep 30, 2022 | 10.81 Mn |
| Dec 31, 2021 | 7.88 Mn |